Mesoblast FY Loss Widens; Stock Down
(RTTNews) - Mesoblast Limited (MESO, MSB.AX) reported that its loss attributable to the owners of the company for fiscal year ended June 30, 2025 widened to US102.14 million from last year's US$87.96 million. But net loss per share narrowed to 8.46 US cents from 8.91 US cents in the prior year.
Annual total revenues from cell therapy products were US$17.2 million, up 191% on prior year. Revenue growth driven by successful launch of Ryoncil in the final quarter.
MESO closed Thursday's regular trading at $15.95 down $0.17 or 1.05%. In the after-hours trading the stock further dropped $1.75 or 10.97%.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.